American Cancer Society Guidelines for breast cancer screening: Update 2003

Ca-A Cancer Journal for Clinicians

Volumn 53, Issue 3, 2003, Pages 141-169

  Smith, Robert A ^a   Saslow, Debbie ^a   Andrews Sawyer, Kimberly ^a   Burke, Wylie ^b   Costanza, Mary E ^c   Evans III, W Phil ^d   Foster Jr , Roger S ^e   Hendrick, Edward ^f   Eyre, Harmon J ^a   Sener, Steven ^g  

^a AMERICAN CANCER SOCIETY   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f NORTHWESTERN MEMORIAL HOSPITAL   (United States)

^g EVANSTON NORTHWESTERN HEALTHCARE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER; BREAST EXAMINATION; CANCER RISK; CANCER SCREENING; COMORBIDITY; EARLY DIAGNOSIS; EVIDENCE BASED MEDICINE; FEMALE; HIGH RISK PATIENT; HUMAN; MAMMOGRAPHY; MEDICAL SOCIETY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; TECHNOLOGY; WORKSHOP;

EID: 0038715898     PISSN: 00079235     EISSN: None     Source Type: Journal    
DOI: 10.3322/canjclin.53.3.141     Document Type: Review

References (184)

1. Tabár L, Duffy SW, Vitak B, et al. The natural history of breast carcinoma: What have we learned from screening? Cancer 1999;86:449-462.
2. Leitch AM, Dodd GD, Costanza M, et al. American Cancer Society guidelines for the early detection of breast cancer: Update 1997. CA Cancer J Clin 1997;47:150-153.
3. Dodd GD. American Cancer Society guidelines on screening for breast cancer. An overview. Cancer 1992;69:1885-1887.
4. Gøtzsche PC, Olsen O. Is screening for breast cancer with mammography justifiable? Lancet 2000;355:129-134.
5. Olsen O, Gøtzsche PC. Systematic review of screening for breast cancer mammography. Available at http://image.thelancet.com/lancet/extra/fullreport.pdf. Accessed April 2003.
6. Olsen O, Gøtzsche PC. Screening for breast cancer with mammography. Cochrane Database Syst Rev 2001;4:CD001877.
7. Olsen O, Gøtzsche PC. Cochrane review on screening for breast cancer with mammography. Lancet 2001;358:1340-1342.
8. Moss S. A trial to study the effect on breast cancer mortality of annual mammographic screening in women starting at age 40. Trial Steering Group. J Med Screen 1999;6:144-148.
9. Hendrick RE, Smith RA, Rutledge JH 3rd, et al. Benefit of screening mammography in women aged 40-49: A new meta-analysis of randomized controlled trials. J Natl Cancer Inst Monogr 1997;22:87-92.
10. Kerlikowske K. Efficacy of screening mammography among women aged 40 to 49 years and 50 to 69 years: Comparison of relative and absolute benefit. J Natl Cancer Inst Monogr 1997;22:79-86.
11. Shapiro S. Periodic screening for breast cancer: The HIP Randomized Controlled Trial. Health Insurance Plan. J Natl Cancer Inst Monogr 1997;22:27-30.
12. Tabár L, Chen HH, Fagerberg G, et al. Recent results from the Swedish Two-County Trial: The effects of age, histologic type, and mode of detection on the efficacy of breast cancer screening. J Natl Cancer Inst Monogr 1997;22:43-47.
13. Andersson I, Janzon L. Reduced breast cancer mortality in women under age 50: Updated results from the Malmo Mammographic Screening Program. J Natl Cancer Inst Monogr 1997;22:63-67.
14. Bjurstam N, Bjorneld L, Duffy SW, et al. The Gothenburg breast screening trial: First results on mortality, incidence, and mode of detection for women ages 39-49 years at randomization. Cancer 1997;80:2091-2099.
15. UK Trial of Early Detection of Breast Cancer group. 16-year mortality from breast cancer in the UK Trial of Early Detection of Breast Cancer. Lancet 1999;353:1909-1914.
16. Alexander FE, Anderson TJ, Brown HK, et al. 14 years of follow-up from the Edinburgh randomised trial of breast-cancer screening. Lancet 1999;353:1903-1908.
17. Miller AB, To T, Baines CJ, et al. Canadian National Breast Screening study-2: 13-year results of a randomized trial in women aged 50-59 years. J Natl Cancer Inst 2000;92:1490-1499.
18. Miller AB, To T, Baines CJ, et al. The Canadian National Breast Screening Study-1: Breast cancer mortality after 11 to 16 years of follow-up. A randomized screening trial of mammography in women age 40 to 49 years. Ann Intern Med 2002;137:305-312.
19. Tabár L, Vitak B, Chen HH, et al. The Swedish Two-County Trial twenty years later. Updated mortality results and new insights from long-term follow-up. Radiol Clin North Am 2000;38:625-651.
20. Nystrom L, Andersson I, Bjurstam N, et al. Long-term effects of mammography screening: Updated overview of the Swedish randomised trials. Lancet 2002;359:909-919.
21. Tabár L, Fagerberg G, Chen HH, et al. Efficacy of breast cancer screening by age. New results from the Swedish Two-County Trial. Cancer 1995;75:2507-2517.
22. Humphrey LL, Helfand M, Chan BK, et al. Breast cancer screening: A summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002;137:347-360.
23. U.S. Preventive Services Task Force. Screening for breast cancer: Recommendations and rationale. Ann Intern Med 2002;137:344-346.
24. Duffy SW, Tabár L, Smith RA. The mammographic screening trials: Commentary on the recent work by Olsen and Gøtzsche. CA Cancer J Clin 2002;52:68-71.
25. Smith RA. Breast cancer screening among women younger than age 50: A current assessment of the issues. CA Cancer J Clin 2000;50:312-336.
26. Tabár L, Smith RA, Duffy SW. Update on effects of screening mammography. Lancet 2002;360:337; author reply:339-340.
27. Veronese U, Forrest P, Wood W, et al. Statement from the chair: Global Summit on Mammographic Screening, 3rd-5th June, 2002: European Institute of Oncology, 2002.
28. Swedish Board of Health and Welfare. Vilka Effekter Har Mammografiscreening? Referat av ett expertmöte anordnat av Socialstyrelsen och Cancerfonden i Stockholm den 15 februari 2002, 2002.
29. Health Council of the Netherlands. The benefit of population screening for breast cancer with mammography. Health Council of the Netherlands, 2002.
30. Duffy SW. Interpretation of breast screening trials: A commentary on the recent paper by Gøtzsche and Olsen. Breast 2001;10:209-212.
31. Tabár L, Vitak B, Tony HH, et al. Beyond randomized controlled trials: Organized mammographic screening substantially reduces breast carcinoma mortality. Cancer 2001;91:1724-1731.
32. Blanks RG, Moss SM, McGahan CE, et al. Effect of NHS breast screening programme on mortality from breast cancer in England and Wales, 1990-8: Comparison of observed with predicted mortality. BMJ 2000;321:665-669.
33. Jonsson H, Tornberg S, Nystrom L, et al. Service screening with mammography in Sweden - evaluation of effects of screening on breast cancer mortality in age group 40-49 years. Acta Oncol 2000;39:617-623.
34. Jonsson H, Nystrom L, Tornberg S, et al. Service screening with mammography of women aged 50-69 years in Sweden: Effects on mortality from breast cancer. J Med Screen 2001;8:152-160.
35. Duffy S, Tabár L, Chen HH, et al. The impact of organized mammographic service screening on breast carcinoma mortality in seven Swedish counties. Cancer 2002;95:458-469.
36. Paci E, Duffy SW, Giorgi D, et al. Quantification of the effect of mammographic screening on fatal breast cancers: The Florence Programme 1990-96. Br J Cancer 2002;87:65-69.
37. Duffy SW, Day NE, Tabár L, et al. Markov models of breast tumor progression: Some age-specific results. J Natl Cancer Inst Monogr 1997;22:93-97.
38. Tabár L, Faberberg G, Day NE, et al. What is the optimum interval between mammographic screening examinations? An analysis based on the latest results of the Swedish two-county breast cancer screening trial. Br J Cancer 1987;55:547-551.
39. Burhenne HJ, Burhenne LW, Goldberg F, et al. Interval breast cancers in the Screening Mammography Program of British Columbia: Analysis and classification. Am J Roentgenol 1994;162:1067-1071; discussion 1072-1075.
40. Michaelson JS, Halpern E, Kopans DB. Breast cancer: Computer simulation method for estimating optimal intervals for screening. Radiology 1999;212:551-560.
41. Michaelson JS, Silverstein M, Wyatt J, et al. Predicting the survival of patients with breast carcinoma using tumor size. Cancer 2002;95:713-723.
42. Michaelson J, Satija S, Moore R, et al. The pattern of breast cancer screening utilization and its consequences. Cancer 2002;94:37-43.
43. Field LR, Wilson TE, Strawderman M, et al. Mammographic screening in women more than 64 years old: A comparison of 1- and 2-year intervals. Am J Roentgenol 1998;170:961-965.
44. Sickles EA. Successful methods to reduce false-positive mammography interpretations. Radiol Clin North Am 2000;38:693-700.
45. Fine MK, Rimer BK, Watts P. Women's responses to the mammography experience. J Am Board Fam Pract 1993;6:546-555.
46. Chang SW, Kerlikowske K, Napoles-Springer A, et al. Racial differences in timeliness of follow-up after abnormal screening mammography. Cancer 1996;78:1395-1402.
47. Lampic C, Thurfjell E, Bergh J, et al. Short- and long-term anxiety and depression in women recalled after breast cancer screening. Eur J Cancer 2001;37:463-469.
48. Schwartz LM, Woloshin S, Sox HC, et al. US women's attitudes to false-positive mammography results and detection of ductal carcinoma in situ: Cross sectional survey. BMJ 2000;320:1635-1640.
49. Steggles S, Lightfoot N, Sellick SM. Psychological distress associated with organized breast cancer screening. Cancer Prev Control 1998;2:213-220.
50. Ernster VL, Barclay J, Kerlikowske K, et al. Incidence of and treatment for ductal carcinoma in situ of the breast JAMA 1996;275:913-918.
51. Sox H. Screening mammography for younger women: Back to basics. Ann Intern Med 2002;137:361-362.
52. Morrow M, Harris JR. Ductal carcinoma in situ and microinvasive carcinoma. In: Harris JR, Lippman ME, Morrow M, Osborne CK, eds. Diseases of the Breast, ed. 2nd Philadelphia: Lippincott Williams & Wilkins, 2000:383-402.
53. Page DL, Dupont WD, Rogers LW, et al. Continued local recurrence of carcinoma 15-25 years after a diagnosis of low grade ductal carcinoma in situ of the breast treated only by biopsy Cancer 1995;76:1197-1200.
54. Connolly JL, Boyages J, Nixon AJ, et al. Predictors of breast recurrence after conservative surgery and radiation therapy for invasive breast cancer. Mod Pathol 1998;11:134-139.
55. Page DL, Simpson JF. Ductal carcinoma in situ - the focus for prevention, screening, and breast conservation in breast cancer. N Engl J Med 1999;340:1499-1500.
56. Ries LAG, Henson DE, Harras A. Survival from breast cancer according to tumor size and nodal status. Surgical Oncology Clin North Am 1994;3:35-50.
57. Shapiro S, Venet W, Strax P, et al. Periodic Screening for Breast Cancer: The Health Insurance Plan Project and its Sequelae. Baltimore: Johns Hopkins Press, 1988.
58. Seidman H, Gelb SK, Silverberg E, et al. Survival experience in the Breast Cancer Detection Demonstration Project. CA Cancer J Clin 1987;37:258-290.
59. Alexander FE, Anderson TJ, Brown HK, et al. The Edinburgh randomised trial of breast cancer screening: Results after 10 years of follow-up. Br J Cancer 1994;70:542-548.
60. Bobo J, Lee N. Factors associated with accurate cancer detection during a clinical breast examination. Ann Epidemiol 2000;10:463.
61. Barton MB, Harris R, Fletcher SW. The rational clinical examination. Does this patient have breast cancer? The screening clinical breast examination: Should it be done? How? JAMA 1999;282:1270-1280.
62. Shapiro S, Strax P, Venet L. Periodic breast cancer screening in reducing mortality from breast cancer. JAMA 1971;215:1777-1785.
63. Newcomer LM, Newcomb PA, Trentham-Dietz A, et al. Detection method and breast carcinoma histology. Cancer 2002;95:470-477.
64. Oestreicher N, White E, Lehman CD, et al. Predictors of sensitivity of clinical breast examination (CBE). Breast Cancer Res Treat 2002;76:73-81.
65. Baxter N. Preventive health care, 2001 update: Should women be routinely taught breast self-examination to screen for breast cancer? CMAJ 2001;164:1837-1846.
66. Harris R, Kinsinger LS. Routinely teaching breast self-examination is dead. What does this mean? J Natl Cancer Inst 2002;94:1420-1421.
67. Austoker J. Breast self examination. BMJ 2003;326:1-2.
68. Stockton D, Davies T, Day N, et al. Retrospective study of reasons for improved survival in patients with breast cancer in east Anglia: Earlier diagnosis or better treatment BMJ 1997;314:472-475; [Published erratum appears in BMJ 1997;314:721].
69. Foster RS Jr., Lang SP, Costanza MC, et al. Breast self-examination practices and breast-cancer stage. N Engl J Med 1978;299:265-270.
70. Greenwald P, Nasca PC, Lawrence CE, et al. Estimated effect of breast self-examination and routine physician examinations on breast-cancer mortality. N Engl J Med 1978;299:271-273.
71. Philip J, Harris WG, Flaherty C, et al. Breast self-examination: Clinical results from a population-based prospective study. Br J Cancer 1984;50:7-12.
72. Semiglazov VF, Moiseenko VM, Manikhas AG, et al. [Interim results of a prospective randomized study of self-examination for early detection of breast cancer (Russia/St.Petersburg/WHO)].Vopr Onkol 1999;45:265-271.
73. Thomas DB, Gao DL, Ray RM, et al. Randomized trial of breast self-examination in Shanghai: Final results. J Natl Cancer Inst 2002;94:1445-1457.
74. Nekhlyudov L, Fletcher SW. Is it time to stop teaching breast self-examination? CMAJ 2001;164:1851-1852.
75. Thomas DB, Gao DL, Self SG, et al. Randomized trial of breast self-examination in Shanghai: Methodology and preliminary results. J Natl Cancer Inst 1997;89:355-365.
76. Administration on Aging. A Profile of Older Americans 2001. Available at: http://www.aoa.gov/aoa/stats/profile/2001/1.html. Accessed 4/25/02.
77. American Cancer Society Surveillance Program. Estimated new cancer cases by sex and age Atlanta: American Cancer Society, 2003.
78. National Cancer Institute. SEER* Stat 4/2, ed. 4.2 Bethesda, MD: National Cancer Institute, 2002.
79. Ries LAG, Eisner MP, Kosary CL, et al. (eds) SEER Cancer Statistics Review, 1973-1999. National Cancer Institute. Bethesda, MD, Available at: http://seer.cancer.gov/csr/1973_1999/. Accessed December 2, 2002.
80. Smith-Bindman R, Kerlikowske K. Is there a downside to elderly women undergoing screening mammography? J Natl Cancer Inst 1998;90:1322-1323.
81. Nixon AJ, Neuberg D, Hayes DF, et al. Relationship of patient age to pathologic features of the tumor and prognosis for patients with Stage I or II breast cancer. J Clin Oncol 1994;12:888-894.
82. Lyman GH, et al. Breast cancer in the older woman: a comparative study of younger and older women with breast cancer. J Gerontol. In press.
83. Holmberg L, Lindgren A, Norden T, et al. Age as a determinant of axillary node involvement in invasive breast cancer. Acta Oncol 1992;31:533-538.
84. McCarthy EP, Burns RB, Freund KM, et al. Mammography use, breast cancer stage at diagnosis, and survival among older women. J Am Geriatr Soc 2000;48:1226-1233.
85. McPherson CP, Swenson KK, Lee MW. The effects of mammographic detection and comorbidity on the survival of older women with breast cancer. J Am Geriatr Soc 2002;50:1061-1068.
86. Rosenberg RD, Hunt WC, Williamson MR, et al. Effects of age, breast density, ethnicity, and estrogen replacement therapy on screening mammographic sensitivity and cancer stage at diagnosis: Review of 183,134 screening mammograms in Albuquerque, New Mexico. Radiology 1998;209:511-518.
87. Faulk RM, Sickles EA, Sollitto RA, et al. Clinical efficacy of mammographic screening in the elderly. Radiology 1995;194:193-197.
88. Kan L, Olivotto IA, Warren Burhenne LJ, et al. Standardized abnormal interpretation and cancer detection ratios to assess reading volume and reader performance in a breast screening program. Radiology 2000;215:563-567.
89. Sickles EA, Ominsky SH, Sollitto RA, et al. Medical audit of a rapid-throughput mammography screening practice: Methodology and results of 27,114 examinations. Radiology 1990;175:323-327.
90. Kerlikowske K, Grady D, Barclay J, et al. Positive predictive value of screening mammography by age and family history of breast cancer. JAMA 1993;270:2444-2450.
91. Smith-Bindman R, Kerlikowske K, Gebretsadik T, et al. Is screening mammography effective in elderly women? Am J Med 2000;108:112-119.
92. Report of the Organizing Committee and Collaborators, Falun Meeting, Falun, Sweden. Breast cancer screening with mammography in women aged 40-49 years. Int J Cancer 1996;68:693-699.
93. Walter LC, Covinsky KE. Cancer screening in elderly patients: A framework for individualized decision making. JAMA 2001;285:2750-2756.
94. Walter LC, Brand RJ, Counsell SR, et al. Development and validation of a prognostic index for 1-year mortality in older adults after hospitalization. JAMA 2001;285:2987-2994.
95. Havlik RJ, Yancik R, Long S, et al. The National Institute on Aging and the National Cancer Institute SEER collaborative study on comorbidity and early diagnosis of cancer in the elderly. Cancer 1994;74:2101-2106.
96. Yancik R, Havlik RJ, Wesley MN, et al. Cancer and comorbidity in older patients: A descriptive profile. Ann Epidemiol 1996;6:399-412.
97. Satariano WA, Ragland DR. The effect of comorbidity on 3-year survival of women with primary breast cancer. Ann Intern Med 1994;120:104-110.
98. West DW, Satariano WA, Ragland DR, et al. Comorbidity and breast cancer survival: A comparison between black and white women. Ann Epidemiol 1996;6:413-419.
99. Piccirillo JF, Feinstein AR. Clinical symptoms and comorbidity: Significance for the prognostic classification of cancer. Cancer 1996;77:834-42.
100. Newschaffer CJ, Bush TL, Penberthy LE, et al. Does comorbid disease interact with cancer? An epidemiologic analysis of mortality in a cohort of elderly breast cancer patients. J Gerontol A Biol Sci Med Sci 1998;53:M372-378.
101. Fleming ST, Rastogi A, Dmitrienko A, et al. A comprehensive prognostic index to predict survival based on multiple comorbidities:A focus on breast cancer. Med Care 1999;37:601-614.
102. Yancik R, Wesley MN, Ries LA, et al. Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. JAMA 2001;285:885-892.
103. Fried LP, Kronmal RA, Newman AB, et al. Risk factors for 5-year mortality in older adults: The cardiovascular health study. JAMA 1998;279:585-592.
104. Standards and Accreditation Committee Medical Guidelines Task Force. Medical Guidelines for Determining Prognosis in Selected Non-Cancer Diseases. 2nd ed. Arlington, VA: National Hospice Organization; 1996.
105. Wolfson C, Wolfson DB, Asgharian M, et al. A reevaluation of the duration of survival after the onset of dementia. N Engl J Med 2001;344:1111-1116.
106. Weinberger M, Saunders AF, Samsa GP, et al. Breast cancer screening in older women: Practices and barriers reported by primary care physicians. J Am Geriatr Soc 1991;39:22-29.
107. Fox SA, Roetzheim RG, Kington RS. Barriers to cancer prevention in the older person. Clin Geriatr Med 1997;13:79-95.
108. Lidbrink E, Elfving J, Frisell J, et al. Neglected aspects of false positive findings of mammography in breast cancer screening: Analysis of false positive cases from the Stockholm trial. BMJ 1996;312:273-276.
109. Barton MB, Elmore JG, Fletcher SW. Breast symptoms among women enrolled in a health maintenance organization: Frequency, evaluation, and outcome. Ann Intern Med 1999;130:651-657.
110. Fentiman IS. Psychological sequelae of screening women with a family history of breast cancer. Eur J Cancer 1998;34:1991-1992.
111. Gilbert FJ, Cordiner CM, Affleck IR, et al. Breast screening:The psychological sequelae of false-positive recall in women with and without a family history of breast cancer. Eur J Cancer 1998;34:2010-2014.
112. Lowe JB, Balanda KP, Del Mar C, et al. Psychologic distress in women with abnormal findings in mass mammography screening. Cancer 1999;85:1114-1118.
113. Lidbrink E, Levi L, Pettersson I, et al. Single-view screening mammography: Psychological, endocrine and immunological effects of recalling for a complete three-view examination. Eur J Cancer 1995;31A:932-933.
114. Lerman C, Daly M, Sands C, et al. Mammography adherence and psychological distress among women at risk for breast-cancer. J Natl Cancer Inst 1993;85:1074-1080.
115. Ernster VL, Ballard-Barbash R, Barlow WE, et al. Detection of ductal carcinoma in situ in women undergoing screening mammography. J Natl Cancer Inst 2002;94:1546-1554.
116. Kelsey JL, Gammon ma Epidemiology of breast cancer. Epidemiol Rev 1990;12:228-240.
117. Ottman R, Pike MC, King MC, et al. Familial breast cancer in a population-based series. Am J Epidemiol 1986;123:15-21.
118. Anderson DE, Badzioch MD. Risk of familial breast cancer. Cancer 1985;56:383-387.
119. Sattin RW, Rubin GL, Webster LA, et al. Family history and the risk of breast cancer. JAMA 1985;253:1908-1913.
120. Schwartz AG, King MC, Belle SH, et al. Risk of breast cancer to relatives of young breast cancer patients. J Natl Cancer Inst 1985;75:665-668.
121. Slattery ML, Kerber RA. A comprehensive evaluation of family history and breast cancer risk. The Utah Population Database. JAMA 1993;270:1563-1568.
122. Colditz GA, Willett WC, Hunter DJ, et al. Family history, age, and risk of breast cancer. Prospective data from the Nurses' Health Study JAMA 1993;270:338-343; [Published erratum appears in JAMA 1993;270:1548].
123. Claus EB, Risch NJ, Thompson WD. Age at onset as an indicator of familial risk of breast cancer. Am J Epidemiol 1990;131:961-972.
124. Lynch HT, Watson P, Conway T, et al. Breast cancer family history as a risk factor for early onset breast cancer. Breast Cancer Res Treat 1988;11:263-267.
125. Claus EB, Risch N, Thompson WD. Genetic analysis of breast cancer in the cancer and steroid hormone study. Am J Hum Genet 1991;48:232-242.
126. Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994;266: 66-71.
127. Wooster R, Neuhausen SL, Mangion J, et al. Localization ofa breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science 1994;265:2088-2090.
128. Hoskins KF, Stopfer JE, Calzone KA, et al. Assessment and counseling for women with a family history of breast cancer. A guide for clinicians. JAMA 1995;273:577-585.
129. Parmigiani G, Berry D, Aguilar O. Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. Am J Hum Genet 1998;62:145-158.
130. Begg CB. On the use of familial aggregation in population-based case probands for calculating penetrance. J Natl Cancer Inst 2002;94:1221-1226.
131. Gail MH, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 1989;81:1879-1886.
132. Colditz GA, Rosner B. Cumulative risk of breast cancer to age 70 years according to risk factor status: Data from the Nurses' Health Study. Am J Epidemiol 2000;152:950-964.
133. Berry DA, Parmigiani G, Sanchez J, et al. Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history. J Natl Cancer Inst 1997;89:227-238.
134. Claus EB, Risch N, Thompson WD. Autosomal dominant inheritance of early-onset breast cancer. Implications for risk prediction. Cancer 1994;73:643-651.
135. Benichou J, Gail MH, Mulvihill JJ. Graphs to estimate an individualized risk of breast cancer. J Clin Oncol 1996;14:103-110.
136. McTiernan A, Kuniyuki A, Yasui Y, et al. Comparisons of two breast cancer risk estimates in women with a family history of breast cancer. Cancer Epidemiol Biomarkers Prev 2001;10: 333-338.
137. Rockhill B, Spiegelman D, Byrne C, et al. Validation of the Gail et al. model of breast cancer risk prediction and implications for chemoprevention. J Natl Cancer Inst 2001;93:358-366.
138. Euhus DM, Smith KC, Robinson L, et al. Pretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCAPRO. J Natl Cancer Inst 2002;94:844-851.
139. Easton DF, Ford D, Bishop DT. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet 1995;56:265-271.
140. Familial breast cancer: Collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Lancet 2001;358:1389-1399.
141. Burke W, Daly M, Garber J, et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium. JAMA 1997;277:997-1003.
142. Brekelmans CT, Seynaeve C, Bartels CC, et al. Effectiveness of breast cancer surveillance in BRCA1/2 gene mutation carriers and women with high familial risk. J Clin Oncol 2001;19: 924-930.
143. Easton DF, Narod SA, Ford D, et al. The genetic epidemiology of BRCA1. Breast Cancer Linkage Consortium. Lancet 1994;344:761.
144. Hildreth NG, Shore RE, Dvoretsky PM. The risk of breast cancer after irradiation of the thymus in infancy. N Engl J Med 1989;321:1281-1284.
145. Hoffman DA, Lonstein JE, Morin MM, et al. Breast cancer in women with scoliosis exposed to multiple diagnostic x-rays. J Natl Cancer Inst 1989;81:1307-1312.
146. Land CE. Radiation and breast cancer risk. Prog Clin Biol Res 1997;396:115-124.
147. Boice JD Jr, Harvey EB, Blettner M, et al. Cancer in the contralateral breast after radiotherapy for breast cancer. N Engl J Med 1992;326:781-785.
148. Law J. Cancers detected and induced in mammographic screening: New screening schedules and younger women with family history. Br J Radiol 1997;70:62-69.
149. Callebaut I, Mornon JP. From BRCA1 to RAP1: A widespread BRCT module closely associated with DNA repair. FEBS Lett 1997;400:25-30.
150. Connor F, Bertwistle D, Mee PJ, et al. Tumorigenesis and a DNA repair defect in mice with a truncating BRCA2 mutation. Nat Genet 1997;17:423-430.
151. Gowen LC, Avrutskaya AV, Latour AM, et al. BRCA1 required for transcription-coupled repair of oxidative DNA damage. Science 1998; 281:1009-1012.
152. Brugarolas J, Jacks T. Double indemnity: p53, BRCA and cancer. p53 mutation partially rescues developmental arrest in BRCA1 and BRCA2 null mice, suggesting a role for familial breast cancer genes in DNA damage repair. Nat Med 1997;3:721-722.
153. Morimatsu M, Donoho G, Hasty P. Cells deleted for BRCA2 COOH terminus exhibit hypersensitivity to gamma-radiation and premature senescence. Cancer Res 1998;58:3441-3447.
154. Pierce LJ, Strawderman M, Narod SA, et al. Effect of radiotherapy after breast-conserving treatment in women with breast cancer and germline BRCA1/2 mutations. J Clin Oncol 2000;18:3360-3369.
155. Pierce LJ, Butler JB, Martel MK, et al. Postmastectomy radiotherapy of the chest wall: Dosimetric comparison of common techniques. Int J Radiat Oncol Biol Phys 2002;52:1220-1230.
156. Chabner E, Nixon A, Gelman R, et al. Family history and treatment outcome in young women after breast-conserving surgery and radiation therapy for early-stage breast cancer. J Clin Oncol 1998;16:2045-2051.
157. Scheuer L, Kauff N, Robson M, et al. Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. J Clin Oncol 2002;20:1260-1268.
158. DeMichele A, Weber BL. Risk management in BRCA1 and BRCA2 mutation carriers: Lessons learned, challenges posed. J Clin Oncol 2002;20:1164-1166.
159. Duffy SW, Tabár L, Smith RA, et al. Risk of breast cancer and risks with breast cancer: The relationship between histologic type and conventional risk factors, disease progression, and survival. Seminars in Breast Disease 1999.
160. Kuhl CK, Schmutzler RK, Leutner CC, et al. Breast MR imaging screening in 192 women proved or suspected to be carriers of a breast cancer susceptibility gene: Preliminary results. Radiology 2000;215:267-279.
161. Tilanus-Linthorst MM, Obdeijn IM, Bartels KC, et al. First experiences in screening women at high risk for breast cancer with MR imaging. Breast Cancer Res Treat 2000;63:53-60.
162. Warner E, Plewes DB, Shumak RS, et al. Comparison of breast magnetic resonance imaging, mammography, and ultrasound for surveillance of women at high risk for hereditary breast cancer. J Clin Oncol 2001;19:3524-3531.
163. Stoutjesdijk MJ, Boetes C, Jager GJ, et al. Magnetic resonance imaging and mammography in women with a hereditary risk of breast cancer. J Natl Cancer Inst 2001;93:1095-1102.
164. Committee on technologies for the early detection of breast cancer. Mammography and Beyond: Developing Technologies for the Early Detection of Breast Cancer. Washington, D.D.: National Academy Press, 2001.
165. Lewin JM, Hendrick RE, D'Orsi CJ, et al. Comparison of full-field digital mammography with screen-film mammography for cancer detection: Results of 4,945 paired examinations. Radiology 2001;218:873-880.
166. Lewin JM, D'Orsi CJ, Hendrick RE, et al. Clinical comparison of full-field digital mammography and screen-film mammography for detection of breast cancer. Am J Roentgenol 2002;179:671-677.
167. Vyborny CJ, Giger ML. Computer vision and artificial intelligence in mammography. Am J Roentgenol 1994;162:699-708.
168. Doi K, MacMahon H, Katsuragawa S, et al. Computer-aided diagnosis in radiology: Potential and pitfalls. Eur J Radiol 1999;31:97-109.
169. Warren Burhenne LJ, Wood SA, D'Orsi CJ, et al. Potential contribution of computer-aided detection to the sensitivity of screening mammography. Radiology 2000;215:554-562.
170. Freer TW, Ulissey MJ. Screening mammography with computer-aided detection: Prospective study of 12,860 patients in a community breast center. Radiology 2001;220:781-786.
171. Zheng B, Ganott MA, Britton CA, et al. Softcopy mammographic readings with different computer-assisted detection cuing environments: Preliminary findings. Radiology 2001;221:633-640.
172. Horsch K, Giger ML, Venta LA, et al. Computerized diagnosis of breast lesions on ultrasound. Med Phys 2002;29:157-164.
173. Penn AI, Bolinger L, Schnall MD, et al. Discrimination of MR images of breast masses with fractal-interpolation function models. Acad Radiol 1999;6:156-163.
174. Drukker K, Giger ML, Horsch K, et al. Computerized lesion detection on breast ultrasound. Med Phys 2002;29:1438-1446.
175. Gordon PB. Ultrasound for breast cancer screening and staging. Radiol Clin North Am 2002;40:431-441.
176. Stavros AT, Thickman D, Rapp CL, et al. Solid breast nodules: Use of sonography to distinguish between benign and malignant lesions. Radiology 1995;196:123-134.
177. Gordon PB, Goldenberg SL. Malignant breast masses detected only by ultrasound. A retrospective review. Cancer 1995;76:626-630.
178. Kolb TM, Lichy J, Newhouse JH. Occult cancer in women with dense breasts: Detection with screening ultrasound - diagnostic yield and tumor characteristics. Radiology 1998;207:191-198.
179. Buchberger W, DeKoekkoek-Doll P, Springer P, et al. Incidental findings on sonography of the breast: Clinical significance and diagnostic workup. Am J Roentgenol 1999;173:921-927.
180. Kolb TM, Lichy J, Newhouse JH. Comparison of the performance of screening mammography, physical examination, and breast US and evaluation of factors that influence them: An analysis of 27,825 patient evaluations. Radiology 2002;225:165-175.
181. O'Driscoll D, Warren R, MacKay J, et al. Screening with breast ultrasound in a population at moderate risk due to family history. J Med Screen 2001;8:106-109.
182. Davis PL, McCarty KS Jr. Sensitivity of enhanced MRI for the detection of breast cancer: New, multicentric, residual, and recurrent. Eur Radiol 1997;7:289-298.
183. Dooley WC, Ljung BM, Veronesi U, et al. Ductal lavage for detection of cellular atypia in women at high risk for breast cancer. J Natl Cancer Inst 2001;93:1624-1632.
184. Enzmann DR, Anglada PM, Haviley C, et al. Providing professional mammography services: Financial analysis. Radiology 2001;219:467-473.